

SUN PHARMACEUTICAL NEW PRODUCT - 30 DAY
REPORT - VERMONT

| | |
|--|--|
| NDC | 10631-0095-10 |
| Trade Name | Halog External Solution 0.1 % |
| Marketing and Pricing Plans | The FDA approved Halog Solution on March 18, 2020 under NDA 017823/S-024. Halog Solution is indicated to treat patients with the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This product is priced to reflect the clinical value of the drug and is priced on par with two other Halog formulations on the market - Halog Ointment and Halog Cream. The prevalence of corticosteroid-responsive dermatoses is unknown. However psoriasis and atopic dermatitis which fall within the category of corticosteroid-responsive dermatoses together represent a good proxy for the number of patients. in the United States, approximately 4.6% of the population is affected with psoriasis1 and nearly 18 million people have AD2. |
| FDA Priority or Breakthrough? | No |
| Acquisition Date | N/A |
| Acquisition Cost | N/A |
| Estimated Avg.number of patients a month | Estimated average of patients per month is unknown to Sun Pharma |